Comparison of Efficacy and Safety of Lispro and Aspart Evaluated by Continuous Glucose Monitoring System in Patients with Newly Diagnosed Type 2 Diabetes.
Bing-Li LiuGuo-Ping YinFeng-Fei LiYun HuJin-Dan WuMao-Yuan ChenLei YeXiao-Fei SuJian-Hua MaPublished in: International journal of endocrinology (2018)
Lispro and aspart had the similar ability to control the glycemic variations in patients with newly diagnosed T2DM. This study was registered with ClinicalTrials.gov, number ChiCTR-IPR-17010338.